Purpose: The hypothesis that oral supplementation of the epilutein/lutein combination could augment the macular pigment optical density (MPOD) in patients with age-related macular degeneration (AMD) was tested. Methods: In a prospective randomized interventional study, 40 consecutive patients with early-stage AMD were recruited. After a 2-week run-in period, patients were randomly treated with a daily oral administration of 8 mg epilutein and 2 mg lutein (group 1) or 10 mg lutein (group 2) for 2 months. At baseline (BL) and 1-month (M1) and 2-month visits (M2), all patients underwent a complete ophthalmological examination, including measurement of MPOD in a 7° area (Visucam 200; Carl Zeiss Meditec, Milan, Italy). Xanthophylls were quantified in plasma, as well as the HDL, non-HDL, and erythrocyte fractions at each study visit. Results: Twenty-one patients (mean age 69.4 ± 6.7 years, 35 eyes) were included in group 1. Mean MPOD was 0.203 ± 0.02 optical density units (ODU) at BL, and increased to 0.214 ± 0.04 ODU at M1 (p = 0.008) and 0.206 ± 0.03 ODU at M2 (p = 0.04). Sixteen patients (mean age 72.0 ± 6.3 years, 29 eyes) were included in group 2. Mean MPOD was 0.215 ± 0.03 at BL, which reduced to 0.202 ± 0.03 ODU at M1 (p = 0.003) and 0.207 ± 0.02 ODU at M2 (p < 0.001). A rise in the systemic level of total xanthophylls was observed at M1 for both groups. At M2, total xanthophylls were significantly increased only in group 1 and decreased in group 2. Conclusion: In patients with early-stage AMD, the administration of lutein in combination with epilutein was associated with an increased MPOD compared to the administration of lutein alone.

Keywords:
Age-related macular degeneration, Lutein, Epilutein, Macular pigment optical density
1.
Landrum JT, Bone RA: Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 2001;385:28-40.
2.
Handelman GJ, Dratz EA, Reay CC, van Kuijk JG: Carotenoids in the human macula and whole retina. Invest Ophthalmol Vis Sci 1988;29:850-855.
3.
Kijlstra A, Tian Y, Kelly ER, Berendschot TT: Lutein: more than just a filter for blue light. Prog Retin Eye Res 2012;31:303-315.
4.
Khachik F, Bernstein P, Garland DL: Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 1997;38:1802-1811.
5.
Bone RA, Landrum JT, Tarsis SL: Preliminary identification of the human macular pigment. Vision Res 1985;25:1531-1535.
6.
Bone RA, Landrum JT, Guerra LH, Ruiz CA: Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 2003;133:992-998.
7.
Granado F, Olmedilla B, Blanco I: Nutritional and clinical relevance of lutein in human health. Br J Nutr 2003;90:487-502.
8.
Hammond BR Jr, Johnson EJ, Russell RM, Krinsky NI, Yeum KJ, Edwards RB, Snodderly DM: Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci 1997;38:1795-1801.
9.
Landrum JT, Bone RA, Joa H, Kilburn MD, Moore LL, Sprague KE: A one year study of the macular pigment: the effect of 140 days of a lutein supplement. Exp Eye Res 1997;65:57-62.
10.
Age-Related Eye Disease Study Research Group, SanGiovanni JP, Chew EY, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Sperduto RD: The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 2007;125:1225-1232.
11.
Ma L, Dou HL, Huang YM, et al: Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial. Am J Ophthalmol 2012;154:625-634.
12.
Schmidl D, Garhöfer G, Schmetterer L: Nutritional supplements in age-related macular degeneration. Acta Ophthalmol 2015;93:105-121.
13.
Tian Y, Kijlstra A, van der Veen RL, Makridaki M, Murray IJ, Berendschot TT: Lutein supplementation leads to decreased soluble complement membrane attack complex sC5b-9 plasma levels. Acta Ophthalmol 2015;93:141-145.
14.
Yoshizako H, Hara K, Takai Y, Kaidzu S, Obana A, Ohira A: Comparison of macular pigment and serum lutein concentration changes between free lutein and lutein esters supplements in Japanese subjects. Acta Ophthalmol 2016;94:e411-e416.
15.
O'Neill ME, Carroll Y, Corridan B, et al: A European carotenoid database to assess carotenoid intakes and its use in a five-country comparative study. Br J Nutr 2001;85:499-507.
16.
Handelman G, Nightingale Z, Lichtenstein A, Schaefer E, Blumberg E: Lutein and zeaxanthin concentrations in plasma after dietary supplementation with egg yolk. Am J Clin Nutr 1999;70:247-251.
17.
Alves-Rodrigues A, Shao A: The science behind lutein. Toxicol Lett 2004;150:57-83.
18.
Deli J, Molnár P, Osz E, Tóth G, Zsila F: Epimerization of lutein to 3′-epilutein in processed foods. Bioorg Med Chem Lett 2004;14:925-928.
19.
Bernstein PS, Li B, Vachali PP, Gorusupudi A, Shyam R, Henriksen BS, Nolan JM: Lutein, zeaxanthin, and meso-zeaxanthin: the basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease. Prog Ret Eye Res 2016;50:34-66.
20.
Khachik F, de Moura FF, Zhao DY, Aebischer CP, Bernstein PS: Transformations of selected carotenoids in plasma, liver, and ocular tissues of humans and in nonprimate animal models. Invest Ophthalmol Vis Sci 2002;43:3383-3392.
21.
Renzi LM, Hammond BR, Dengler M, Melissa, Roberts R: The relation between serum lipids and lutein and zeaxanthin in the serum and retina: results from cross-sectional, case-control and case study designs. Lipids Health Dis 2012;11:33.
22.
Li B, Vachali P, Frederick JM, Bernstein PS: Identification of StARD3 as a lutein-binding protein in the macula of the primate retina. Biochemistry 2011;50:2541-2549.
23.
Khachik F, de Moura FF, Chew EY, Douglass LW, Ferris FL 3rd, Kim J, Thompson DJ: The effect of lutein and zeaxanthin supplementation on metabolites of these carotenoids in the serum of persons aged 60 or older. Invest Ophthalmol Vis Sci 2006;47:5234-5242.
24.
Khachik F, London E, de Moura FF, Johnson M, Steidl S, Detolla L, Shipley S, Sanchez R, Chen XQ, Flaws J, Lutty G, McLeod S, Fowler B: Chronic ingestion of (3R,3′R,6'R)-lutein and (3R,3′R)-zeaxanthin in the female rhesus macaque. Invest Ophthalmol Vis Sci 2006;47:5476-5486.
25.
Reynolds R, Rosner B, Seddon JM: Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration. Ophthalmology 2010;117:1989-1995.
26.
Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB, Mares JA: Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-Related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol 2006;124:1151-1162.
27.
Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005-2015.
28.
Nakagawa K, Kiko T, Hatade K, et al: Development of a high-performance liquid chromatography-based assay for carotenoids in human red blood cells: application to clinical studies. Anal Biochem 2008;381:129-134.
29.
Miyazawa T, Nakagawa K, Kimura F, Nakashima Y, Maruyama I, Higuchi O, Miyazawa T: Chlorella is an effective dietary source of lutein for human erythrocytes. J Oleo Sci 2013;62:773-779.
30.
Eidenberger T: Combination of Carotenoids and Epi-Lutein. 2013, patent US20110144200A1.
31.
Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR; Beckman Initiative for Macular Research Classification Committee: Clinical classification of age-related macular degeneration. Ophthalmology 2013;120:844-851.
32.
Vishwanathan R, Gendron CM, Goodrow-Kotyla EF, Wilson T, Nicolosic R: Increased consumption of dietary cholesterol, lutein, and zeaxanthin as egg yolks does not decrease serum concentrations and lipoprotein distribution of other carotenoids, retinol, and tocopherols. Nutr Res 2010;30:747-755.
33.
Eidenberger T: Process for the Manufacture of a Composition Containing at Least One Xanthophyll. 2009, patent US7812198 B2.
34.
Molnar P, Deli J, Osz E, Toth G, Zsila F, Herrero C, Landrum JT: Preparation and spectroscopic characterization of 3′-oxolutein. Lett Org Chem 2006;3:723-734.
35.
Schiedt K, Leuenberger FJ, Vecchi M, Glinz E: Absorption, retention and metabolic transformations of carotenoids in rainbow trout, salmon and chicken. Pure Appl Chem 1985;57:685-692.
36.
Bernstein PS, Khachik F, Carvalho LS, Muir GJ, Zhao D-Y, Katz NB: Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp Eye Res 2001;72:215-223.
37.
Hartmann D, Thürmann PA, Spitzer V, Schalch W, Manner B, Cohn W: Plasma kinetics of zeaxanthin and 3′-dehydro-lutein after multiple oral doses of synthetic zeaxanthin. Am J Clin Nutr 2004;79:410-417.
38.
Bernstein PS, Delori FC, Richer S, van Kuijk FJ, Wenzel AJ: The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders. Vision Res 2010;50:716-728.
39.
Burrows TL, Williams R, Rollo M, Wood L, Garg ML, Jensen M, Collins CE: Plasma carotenoid levels as biomarkers of dietary carotenoid consumption: a systematic review of the validation studies. J Nutr Intermed Metab 2015;2:15-64.
40.
Arnold C, Winter L, Fröhlich K, Jentsch S, Dawczynski J, Jahreis G, Böhm V: Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmol 2013;131:564-572.
41.
Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE: Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 2001;42:235-240.
42.
Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME: Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 2001;42:439-446.
43.
Trieschmann M, Spital G, Lommatzsch A, van Kuijk E, Fitzke F, Bird AC, Pauleikhoff D: Macular pigment: quantitative analysis on autofluorescence images. Graefes Arch Clin Exp Ophthalmol 2003;241:1006-1012.
44.
Cho E, Hankinson SE, Rosner B, Willett WC, Colditz GA: Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. Am J Clin Nutr 2008;87:1837-1843.
45.
Ciulla TA, Hammond BR Jr: Macular pigment density and aging, assessed in the normal elderly and those with cataracts and age-related macular degeneration. Am J Ophthalmol 2004;138:582-587.
46.
Curran-Celentano J, Hammond BR Jr, Ciulla TA, Cooper DA, Pratt LM, Danis RB: Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr 2001;74:796-802.
47.
Schweitzer D, Jentsch S, Dawczynski J, Hammer M, Wolf-Schnurrbusch UE, Wolf S: Simple and objective method for routine detection of the macular pigment xanthophyll. J Biomed Opt 2010;15:061714.
48.
Berendschot TT, van Norren D: Objective determination of the macular pigment optical density using fundus reflectance spectroscopy. Arch Biochem Biophys 2004;430:149-155.
49.
Dragostinoff N, Werkmeister RM, Kaya S, et al: Short- and midterm repeatability of macular pigment optical density measurements using spectral fundus reflectance. Graefes Arch Clin Exp Ophthalmol 2012;250:1261-1266.
50.
Kaya S, Weigert G, Pemp B, et al: Comparison of macular pigment in patients with age-related macular degeneration and healthy control subjects - a study using spectral fundus reflectance. Acta Ophthalmol 2012;90:e399-e403.
51.
Ji Y, Zhang X, Wu K, Su Y, Zuo C, Chen H, Li M, Wen F: Macular pigment optical density in a healthy Chinese population. Acta Ophthalmol 2015;93:e550-e555.
52.
Obana A, Tanito M, Gohto Y, Okazaki S, Gellermann W, Bernstein PS: Changes in macular pigment optical density and serum lutein concentration in Japanese subjects taking two different lutein supplements. PLoS One 2015;10:e0139257.
53.
Trieschmann M, Beatty S, Nolan JM, Hense HW, Heimes B, Austermann U, Fobker M, Pauleikhoff D: Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res 2007;84:718-728.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.